Drug Trial Radar · NCT07418177
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Oct 14, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- HELP Therapeutics Co., Ltd.
- First posted
- Feb 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular Degeneration(AMD) Patients.
Conditions
- AMD - Age-Related Macular Degeneration
Interventions
hiPSC-RPEsBiological
hiPSC-RPEs transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment-Related Adverse EventsTime frame: Within 2 years after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.